Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis.
OBJECTIVES: Oxidative stress plays an important role in the pathogenesis of multiple sclerosis (MS). Though reactive oxygen species (ROS) are produced by various mechanisms, xanthine oxidase (XO) is a major enzyme generating ROS in the context of inflammation. The objectives of this study were to in...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3738596?pdf=render |
id |
doaj-5cb4118c5c194c60aee10eca784a1c56 |
---|---|
record_format |
Article |
spelling |
doaj-5cb4118c5c194c60aee10eca784a1c562020-11-25T01:19:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7132910.1371/journal.pone.0071329Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis.Josephe Archie HonoratMakoto KinoshitaTatsusada OkunoKazushiro TakataToru KodaSatoru TadaTakashi ShirakuraHarutoshi FujimuraHideki MochizukiSaburo SakodaYuji NakatsujiOBJECTIVES: Oxidative stress plays an important role in the pathogenesis of multiple sclerosis (MS). Though reactive oxygen species (ROS) are produced by various mechanisms, xanthine oxidase (XO) is a major enzyme generating ROS in the context of inflammation. The objectives of this study were to investigate the involvement of XO in the pathogenesis of MS and to develop a potent new therapy for MS based on the inhibition of ROS. METHODS: XO were assessed in a model of MS: experimental autoimmune encephalomyelitis (EAE). The contribution of XO-generated ROS to the pathogenesis of EAE was assessed by treating EAE mice with a novel XO inhibitor, febuxostat. The efficacy of febuxostat was also examined in in vitro studies. RESULTS: We showed for the first time that the expression and the activity of XO were increased dramatically within the central nervous system of EAE mice as compared to naïve mice. Furthermore, prophylactic administration of febuxostat, a XO inhibitor, markedly reduced the clinical signs of EAE. Both in vivo and in vitro studies showed infiltrating macrophages and microglia as the major sources of excess XO production, and febuxostat significantly suppressed ROS generation from these cells. Inflammatory cellular infiltration and glial activation in the spinal cord of EAE mice were inhibited by the treatment with febuxostat. Importantly, therapeutic efficacy was observed not only in mice with relapsing-remitting EAE but also in mice with secondary progressive EAE by preventing axonal loss and demyelination. CONCLUSION: These results highlight the implication of XO in EAE pathogenesis and suggest XO as a target for MS treatment and febuxostat as a promising therapeutic option for MS neuropathology.http://europepmc.org/articles/PMC3738596?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Josephe Archie Honorat Makoto Kinoshita Tatsusada Okuno Kazushiro Takata Toru Koda Satoru Tada Takashi Shirakura Harutoshi Fujimura Hideki Mochizuki Saburo Sakoda Yuji Nakatsuji |
spellingShingle |
Josephe Archie Honorat Makoto Kinoshita Tatsusada Okuno Kazushiro Takata Toru Koda Satoru Tada Takashi Shirakura Harutoshi Fujimura Hideki Mochizuki Saburo Sakoda Yuji Nakatsuji Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. PLoS ONE |
author_facet |
Josephe Archie Honorat Makoto Kinoshita Tatsusada Okuno Kazushiro Takata Toru Koda Satoru Tada Takashi Shirakura Harutoshi Fujimura Hideki Mochizuki Saburo Sakoda Yuji Nakatsuji |
author_sort |
Josephe Archie Honorat |
title |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
title_short |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
title_full |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
title_fullStr |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
title_full_unstemmed |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
title_sort |
xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
OBJECTIVES: Oxidative stress plays an important role in the pathogenesis of multiple sclerosis (MS). Though reactive oxygen species (ROS) are produced by various mechanisms, xanthine oxidase (XO) is a major enzyme generating ROS in the context of inflammation. The objectives of this study were to investigate the involvement of XO in the pathogenesis of MS and to develop a potent new therapy for MS based on the inhibition of ROS. METHODS: XO were assessed in a model of MS: experimental autoimmune encephalomyelitis (EAE). The contribution of XO-generated ROS to the pathogenesis of EAE was assessed by treating EAE mice with a novel XO inhibitor, febuxostat. The efficacy of febuxostat was also examined in in vitro studies. RESULTS: We showed for the first time that the expression and the activity of XO were increased dramatically within the central nervous system of EAE mice as compared to naïve mice. Furthermore, prophylactic administration of febuxostat, a XO inhibitor, markedly reduced the clinical signs of EAE. Both in vivo and in vitro studies showed infiltrating macrophages and microglia as the major sources of excess XO production, and febuxostat significantly suppressed ROS generation from these cells. Inflammatory cellular infiltration and glial activation in the spinal cord of EAE mice were inhibited by the treatment with febuxostat. Importantly, therapeutic efficacy was observed not only in mice with relapsing-remitting EAE but also in mice with secondary progressive EAE by preventing axonal loss and demyelination. CONCLUSION: These results highlight the implication of XO in EAE pathogenesis and suggest XO as a target for MS treatment and febuxostat as a promising therapeutic option for MS neuropathology. |
url |
http://europepmc.org/articles/PMC3738596?pdf=render |
work_keys_str_mv |
AT josephearchiehonorat xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT makotokinoshita xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT tatsusadaokuno xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT kazushirotakata xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT torukoda xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT satorutada xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT takashishirakura xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT harutoshifujimura xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT hidekimochizuki xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT saburosakoda xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis AT yujinakatsuji xanthineoxidasemediatesaxonalandmyelinlossinamurinemodelofmultiplesclerosis |
_version_ |
1725139050686316544 |